MHUAF Meihua International Medical Technologies Co., Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1835615 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-36.2%
TTM net income YoY-37.5%
TTM EPS YoY-54.5%
Revenue 3-yr CAGR-15.8%
Net income 3-yr CAGR2.8%
Margins
Gross margin31.0%
Operating margin13.4%
Net margin11.0%
FCF margin0.9%
EBITDA margin14.3%
Returns
ROE3.9%
ROA3.4%
ROIC (approx.)3.8%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio8.42x
Interest coverage34.30x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio3.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $61.79M | $96.91M |
| Cost of revenue | $42.63M | $63.61M |
| Gross profit | $19.16M | $33.30M |
| R&D expense | $2.38M | $3.46M |
| SG&A expense | $3.21M | $7.78M |
| Operating income | $8.28M | $14.31M |
| Interest expense | $241,523 | $1.51M |
| Pretax income | $9.41M | $13.63M |
| Income tax | $2.62M | $2.79M |
| Net income | $6.78M | $10.84M |
| EBITDA | $8.82M | $14.86M |
| EPS (basic) | 18.04 | 39.62 |
| EPS (diluted) | 18.04 | 39.62 |
| Weighted avg. shares (diluted) | 376,035 | 273,717 |
| Banking | ||
| Net interest income | — | -$1.51M |
| Balance sheet | ||
| Cash & equivalents | $15.15M | $17.29M |
| Receivables | $84.33M | $78.66M |
| Inventory | $1.70M | $1.41M |
| Current assets | $153.58M | $143.44M |
| PP&E, net | $7.70M | $7.89M |
| Goodwill | — | $7.90M |
| Intangibles | $446,495 | $443,035 |
| Total assets | $207.18M | $186.24M |
| Current liabilities | $18.25M | $27.26M |
| Short-term debt | $8.99M | $7.95M |
| Total liabilities | $18.25M | $27.26M |
| Shareholders' equity | $188.93M | $158.98M |
| Shares outstanding | — | 31.90M |
| Cash flow statement | ||
| Operating cash flow | $569,883 | $14.64M |
| Capital expenditure | $15,629 | $133,550 |
| Free cash flow | $554,254 | $14.50M |
| Investing cash flow | -$20.13M | -$20.42M |
| Financing cash flow | $17.19M | $6.21M |
| Depreciation & amortization | $533,963 | $543,658 |
| Share buybacks | — | $200,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.